The Efficacy and Safety of Temozolomide in Patients With MPPGL
Status:
Completed
Trial end date:
2023-01-01
Target enrollment:
Participant gender:
Summary
Metastatic pheochromocytoma / paraganglioma (MPP) are rare while the prognosis was poor.
Temozolomide (TMZ) is a novel oral alkylation chemotherapeutic agent. TMZ has been
recommended in National Comprehensive Cancer Network (NCCN) Guidelines Version 1.2019 for
treating MPP patients.However, studies investigating TMZ efficacy in MPP patients are
extremely limited. The largest study involved only 15 patients till date. The safety and
efficacy of TMZ treatment in MPP patients need to be verified in larger studies.